10-K: bioAffinity Technologies Reports Increased Revenue, Outlines Strategic Actions in Annual 10-K Filing

bioAffinity Technologies' 10-K filing reveals a 270% revenue increase driven by the PPLS acquisition, alongside strategic cost-saving measures and continued focus on CyPath Lung commercial growth.

Summary

• bioAffinity Technologies' 10-K filing summarizes the company's business, financial performance, and future outlook.
• The company develops noninvasive diagnostics for early-stage lung cancer and other lung diseases, utilizing flow cytometry and AI-driven analysis.
• Key financial highlights for 2024 include a 270% increase in consolidated revenue to $9.4 million, primarily due to the acquisition of PPLS.
• CyPath Lung testing revenue saw a 1,400% increase to $0.5 million, driven by a significant rise in test results delivered.
• The company raised approximately $6.9 million in gross proceeds from equity transactions to fund operating activities.
• Strategic actions are underway to improve financial performance, including $4 million in annual cost savings at PPLS and increased resources for CyPath Lung sales.
• The company is progressing with its FDA pivotal study, with a protocol submitted for approval and VA medical centers expressing interest in participation.
• Recent case studies highlight the clinical benefits of CyPath Lung in preventing unnecessary biopsies and aiding in cancer diagnosis.
• The company completed public and private offerings, including warrant exercises and registered direct offerings, to bolster its financial position.
• The company is building on its flow cytometry platform to develop precision diagnostics for COPD and asthma, with patient studies expected in 2026.
• OncoSelect Therapeutics research has identified potential cancer therapies, with plans to present findings and seek strategic partners.
• The company faces risks related to its financial position, diagnostic product development, intellectual property rights, and government regulations.
• The company is an emerging growth company and a smaller reporting company, which allows for certain reduced reporting requirements.
• The company employs 57 employees, with a focus on attracting and retaining skilled professionals.
• The company is subject to various government regulations, including FDA requirements for medical devices and LDTs, as well as CLIA standards for clinical laboratories.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there's positive revenue growth and strategic initiatives, the company faces significant financial challenges and uncertainties, including a going concern warning.

Positives

• Significant revenue growth driven by the acquisition of PPLS and increased CyPath Lung testing.
• Proactive measures to improve financial performance through cost savings and strategic focus.
• Progress in advancing the FDA pivotal study for CyPath Lung.
• Positive clinical case studies demonstrating the value of CyPath Lung in patient care.
• Successful completion of public and private offerings to strengthen the company's financial position.
• Expansion of the company's platform technology to develop diagnostics for COPD and asthma.
• Advancement of OncoSelect Therapeutics research with potential for broad-spectrum cancer treatments.

Negatives

• The company has incurred significant losses and negative cash flows from operations since inception.
• The company has an accumulated deficit of approximately $53.6 million as of December 31, 2024.
• The company's independent registered public accounting firm has included an explanatory paragraph in its opinion that accompanies the audited consolidated financial statements as of and for the year ended December 31, 2024, indicating that the company's current liquidity position raises substantial doubt about its ability to continue as a going concern.
• The company is dependent on its pathology laboratory PPLS to offer and perform CyPath Lung.
• The company faces intense competition in the biotechnology and pharmaceutical industries.
• The company's stock price has fluctuated in the past, has recently been volatile, and may be volatile in the future, and as a result, investors in the company's Common Stock could incur substantial losses.
• The company's Common Stock has often been thinly traded, so investors may be unable to sell at or near ask prices or at all if investors need to sell shares to raise money or otherwise desire to liquidate their shares.

Risks

• Reliance on additional funding to execute the business plan.
• Uncertainty regarding the success of clinical trials and regulatory approvals.
• Competition from other diagnostic and therapeutic companies.
• Potential product liability and pre-clinical and clinical liability risks.
• Dependence on third parties for manufacturing, marketing, and clinical trial management.
• Risk of security breaches and disruptions to information technology systems.
• Potential changes in government regulations and healthcare policies.
• Failure to meet continued listing requirements of The Nasdaq Capital Market.
• Volatility in the company's stock price and limited trading volume.
• Potential limitations on the use of net operating loss carryforwards.

Future Outlook

The company expects to continue to incur significant operating losses for the foreseeable future as it continues the development of its diagnostic tests and advances its diagnostic tests through clinical trials; however, it does expect revenue to increase due to accelerating sales of CyPath Lung and cost-saving measures it recently instituted at PPLS. The company intends to seek strategic partners for its therapeutic discoveries related to selective broad-spectrum cancer treatments through pre-clinical and clinical development. The company anticipates raising additional cash needed through the private or public sales of equity or debt securities, collaborative arrangements, or a combination thereof to continue to fund its operations and develop its products.

Industry Context

The global lung cancer diagnostic market is projected to grow from an estimated $15.1 billion in 2023 to $34.8 billion by the end of 2034, with a compound annual growth rate (CAGR) of 7.9%, according to a market research report issued by Transparency Market Research in October 2024. The company has the potential to play a significant role in the global cancer diagnostic market because it holds a strong and expanding IP portfolio for CyPath Lung, a noninvasive, cost-effective, and high performing test that has the potential to better patient outcomes.

Comparison to Industry Standards

• CyPath Lung has not been tested directly against its competitors products, but a comparison of the published performance numbers suggests CyPath Lung is among the highest performing tests on the market.
• CyPath Lung performs similar to current Standard of Care, including more invasive and riskier diagnostic procedures.
• CyPath Lung has shown high specificity and sensitivity that is similar to far more invasive and more expensive procedures currently used to detect lung cancer.
• A 2024 study authored by Michael Morris, M.D., and Sheila Habib, M.D., reported on CyPath Lungs economic impact when used as companion test to the current Standard of Care predicting savings of more than $2,700 per Medicare patient and more than $6,400 per patient with private payer insurance who have pulmonary nodules sized less than 30 mm.

Stakeholder Impact

• Shareholders face potential dilution and volatility in stock price.
• Employees may be affected by cost-saving measures and potential changes in operations.
• Customers and patients could benefit from improved diagnostic tests and potential therapeutic products.
• Suppliers and creditors may be impacted by the company's financial condition and ability to meet obligations.

Next Steps

• Continue the development of diagnostic tests and advance diagnostic tests through clinical trials.
• Seek strategic partners for therapeutic discoveries related to selective broad-spectrum cancer treatments through pre-clinical and clinical development.
• Raise additional cash needed through the private or public sales of equity or debt securities, collaborative arrangements, or a combination thereof to continue to fund operations and develop products.
• Actively monitor the bid price of the company's Common Stock and will consider available options to regain compliance with the Nasdaq listing requirements.

Key Dates

Keywords

CyPath Lung, lung cancer, diagnostics, PPLS, FDA, clinical trials, revenue, warrants, equity, financing, OncoSelect, COPD, asthma, biotechnology, healthcare